Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Trump's CDC, FDA nominees, Merck, Alnylam
Trump's health nominees, including CDC's Dave Weldon and FDA's Marty Makary, could bring significant changes. Merck's Winrevair showed positive results in a Phase 3 trial, while Cassava's sumifilam failed in Alzheimer's treatment. FDA approved BridgeBio's Attruby for ATTR-CM, priced lower than Pfizer's drugs. Singulair linked to mental health issues. Sarclisa trials highlighted racial disparities in clinical trial composition.
FDA Study Adds To Concerns That Asthma Drug Can Harm Mental Health
FDA study links asthma drug Singulair (montelukast) to severe mental health issues and suicide, though more data is needed to understand its impact on the nervous system.
FDA Links Asthma Drug Singulair To Mental Health Side Effects, Suicides
FDA study links asthma drug Singulair (montelukast) to severe mental health issues and suicides, prompting a black box warning in 2020. Research shows montelukast binds to brain receptors critical for psychiatric functioning, though direct causality and risk factors remain unclear.
FDA Highlights and Health Concerns: From Heart Drugs to Mpox Updates
FDA approves BridgeBio's Attruby for ATTR-CM, first new treatment in area dominated by Pfizer's Vyndaqel. Research finds healthy breast cells may show genetic changes similar to invasive breast cancer. Canada confirms first clade I mpox case amid African outbreak. Canadian neurosurgeons, in collaboration with Neuralink, recruit patients for brain-device interface study. FDA discusses Singulair's potential mental health impact.
US researchers find widely used asthma drug impacts the brain
U.S. researchers found that the asthma drug Singulair (montelukast) may cause serious mental health issues, prompting the FDA to add a 'black box' warning in 2020. Laboratory tests showed montelukast binds to brain receptors, similar to drugs known for neuropsychiatric effects. Despite this, the FDA does not plan to update the drug label further.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath